Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PVLA
PVLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PVLA News
Palvella Therapeutics Announces Clinical Results Presentation at ISSVA 2026
6h ago
Newsfilter
Palvella Appoints New Board Member to Drive Rare Disease Innovation
Apr 13 2026
Newsfilter
Palvella Appoints New Senior Vice President of Sales
Apr 07 2026
Newsfilter
Palvella Therapeutics Reports FY Loss and Cash Position
Mar 31 2026
seekingalpha
Palvella Plans NDA Submission for QTORIN™ Rapamycin in 2026
Mar 31 2026
Newsfilter
Review Highlights Treatment Strategies for Lymphatic Malformations
Mar 30 2026
Newsfilter
Palvella Launches QTORIN™ Novel Skin Treatment Drug
Mar 27 2026
Newsfilter
Palvella COO Sells Stock Options Amid Strong Market Surge
Mar 25 2026
Fool
Palvella Executive Sells Shares Amid Positive Developments
Mar 25 2026
NASDAQ.COM
Palvella Therapeutics Director Increases Stake in Public Offering
Mar 24 2026
Fool
Palvella Launches Awareness Campaign for Microcystic Lymphatic Malformations
Mar 10 2026
Newsfilter
Palvella Closes $230 Million Upsized Public Offering
Mar 02 2026
Newsfilter
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Palvella Therapeutics Prices $200 Million Upsized Public Offering
Feb 26 2026
NASDAQ.COM
Palvella Therapeutics Successfully Prices Upsized Public Offering
Feb 26 2026
Yahoo Finance
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
Show More News
